Last updated: February 22, 2026
What Is NDC 51407-0663?
NDC 51407-0663 refers to a specific drug identified by the National Drug Code system. Based on available data, it corresponds to Doxorubicin Hydrochloride Injection, USP. This chemotherapeutic agent is used in treatment regimens for various cancers, including breast, bladder, ovarian, and lymphoma.
Market Overview
Market Size and Demand
The global oncology drug market was valued at approximately USD 150 billion in 2022, projected to grow at a CAGR of 7% until 2030 [1]. Doxorubicin remains a cornerstone in chemotherapy protocols, maintaining significant demand in both research and clinical use.
Distribution Channels
Primarily supplied through hospital and retail pharmacies, with increasing availability in compounding and specialty drug channels for personalized treatments. Reimbursement policies from Medicare, Medicaid, and private insurers influence market penetration.
Competitive Landscape
Doxorubicin’s patent expired decades ago, leading to a majority of market share held by generic manufacturers. Major players include Pfizer, Teva, Sandoz, and Hikma, producing sterile injectables under various brand and generic labels.
Regulatory Status
The FDA approved doxorubicin injection for adult and pediatric indications. Orphan drug designations exist for specific rare cancers, but the drug generally holds a broad approved scope.
Price Trends and Projections
Current Pricing Structure
- Average Wholesale Price (AWP): Approximately USD 60-80 per vial (50 mg); lower for smaller doses based on hospital procurement agreements [2].
- Reimbursement Rates: Varies by payer, often aligned with average sales prices (ASP) plus markup agreements.
Factors Influencing Price Stability
- Generic Competition: Maintains downward pressure on prices.
- Manufacturing Costs: Stable due to mature production processes.
- Supply Chain Dynamics: Single-source shortages can cause price spikes.
- Reimbursement Policies: Shifts toward value-based care impact pricing models.
Future Price Projection
Over the next five years, Doxorubicin injection prices are expected to decrease modestly, averaging 3-5% annually, driven by increasing generic competition and manufacturing efficiencies [3].
| Year |
Estimated Price (per 50 mg vial) |
Comments |
| 2023 |
USD 70 |
Current average price |
| 2025 |
USD 66 |
Slight decline due to competition |
| 2027 |
USD 63 |
Market stabilization, possible slight decrease |
Impact of Biosimilars
While biosimilars are more common for biologics, the analogs of small molecule chemotherapeutics like doxorubicin see limited biosimilar entry. Nonetheless, if biosimilar options emerge, downward pressure on pricing could accelerate.
Market Risks and Opportunities
Risks
- Supply Disruptions: Shortages may elevate prices temporarily.
- Regulatory Changes: Price controls or reimbursement reforms can reduce margins.
- Market Saturation: Increased use of targeted therapies may reduce reliance on doxorubicin.
Opportunities
- Combination Therapies: Developing formulations that combine doxorubicin with other agents can expand use cases.
- Regional Expansion: Growing healthcare infrastructure in emerging markets presents sales opportunities.
Summary
Doxorubicin injection (NDC 51407-0663) maintains a stable position within the oncology market. Prices currently experience slight declines, supported by extensive generic competition. Future trends suggest continued mild price reductions, with potential for growth in emerging markets and new combination therapy applications.
Key Takeaways
- The drug corresponds to doxorubicin hydrochloride injection, a widely used chemotherapeutic.
- Market demand is sustained by its role in standard cancer treatments.
- Prices are approximately USD 70 per 50-mg vial, declining gradually due to competition.
- Future price outlook projects a 3-5% annual decrease over five years.
- Market risks include supply disruptions and regulatory pressures; opportunities lie in combination therapies and regional expansion.
FAQs
1. What factors influence doxorubicin pricing?
Pricing is affected by patent expiration, generic competition, manufacturing costs, supply chain stability, and payer reimbursement policies.
2. Are biosimilars an option for doxorubicin?
No; biosimilars are typically for biologics. Doxorubicin is a small molecule chemotherapeutic, limiting biosimilar development.
3. How does competition affect market prices?
High generic competition leads to price reductions, stabilizing or decreasing the average market price.
4. Which regions present growth opportunities?
Emerging markets in Asia, Latin America, and Africa are expanding their oncology treatment access, creating opportunities for increased sales.
5. What is the main challenge for doxorubicin market stability?
Supply chain disruptions and shifts in treatment protocols toward targeted therapies are primary challenges.
References
[1] MarketWatch. (2022). Oncology Drug Market Size & Trends.
[2] Red Book. (2023). Wholesale drug prices.
[3] IQVIA. (2022). Oncology market forecasts.
(End of report)
